Interview with Melvin Oscar D'souza, Managing Director, Novo Nordisk India…
Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this…
Address: Novo Nordisk India Limited, Plot No.32, 47-50, EPIP Area, Whiltefield, Bangalore – 560 066, India
Tel: +91 80 4030 3200
Web: http://www.novonordisk.co.in/documents/home_page/document/index.asp
Novo Nordisk India story
The genesis of Novo Nordisk India goes back to 1990 when a liaison office of Novo Nordisk A/S, was set up in Mumbai. Prior to this Novo Nordisk A/S products were marketed in India through various other companies. Even then, Novo Nordisk was involved in creating awareness in diabetes care with the help of healthcare professionals in India.
On April 1, 1994, Novo Nordisk (I) Pvt. Ltd. was set up with its headquarters in Bangalore with 26 employees. It has now been rechristened as Novo Nordisk India Private Limited.
In 1998, recognising the intense need to provide awareness and education in healthcare in India, the Novo Nordisk Education Foundation (NNEF) was founded. NNEF is a non-profit organisation, with a mission of ‘Enhancing healthcare through awareness and education’.
Novo Nordisk India’s portfolio of products and services deals with therapy areas in Diabetes, Human Growth Hormone and Haemostasis Management.
Novo Nordisk is synonymous with diabetes care inIndia . Novo Nordisk has introduced products and services hitherto not seen in the area of diabetes care in the country.
Over the last decade Novo Nordisk has been able to ensure that there is a marked improvement in the way people with diabetes live and work.
As part of our efforts to be at the forefront of bringing information to people with diabetes in India, we have attempted to highlight various aspects of diabetes which you would like to know about.
As part of our activities, we have always endeavoured to stay in touch with persons with diabetes as well as the medical fraternity.
Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this…
Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this…
Writing in the March 2022 edition of DIA’s Global Forum magazine, Ananya Chakraborty from the Vydehi Institute of Medical Sciences & Research Centre outlines the key factors behind India’s successful…
The Indian pharma market clocked up double-digit growth of around 15 percent in 2021 (compared to three percent in 2020), driven primarily – but not only – by products related…
The latest news from Indian pharm and healthcare, including Piramal Enterprises’ decision to demerge and list its pharma arm, the country’s 15 pharma billionaires, Danish CNS firm Lundbeck’s decision to…
The latest from Indian pharma, including the year-to-year 51.5 percent growth of the pharma market in April, Lilly’s partnership with three generics makers to expand the availability of its arthritis…
The latest news from Indian pharma, including a 200 percent boost for the country’s pharmaceutical industry in the latest national budget; predictions of rapid growth in the coming decade; Cipla’s…
The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands to grow by between 12 and 14 percent in the next…
Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with India-developed vaccine candidates moving swiftly toward Phase I and II human trials…
COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and active pharmaceutical ingredients for the last month. With restrictions beginning to ease up, some manufacturing…
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market. Now accounting for over 90 percent of all prescriptions dispensed in…
The ongoing coronavirus outbreak and the subsequent shutdown of factories in China is having severe repercussions for Indian pharma manufacturers and could lead to global shortages. Shortages and Price…
Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the coronavirus, to regulatory reform, the spike in USFDA warning letters…
Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an expansion into the Australia…
See our Cookie Privacy Policy Here
